Fiche publication
Date publication
janvier 2026
Journal
JCO precision oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAVIER Laure
,
Dr KAMINSKY Marie-Christine
Tous les auteurs :
Blanc-Durand F, You B, Adnani Y, De Rauglaudre G, Ray-Coquard I, Combe P, Abdeddaim C, Joly F, Ferron G, Deldycke C, Colomban O, Kaminsky MC, Meunier J, Alexandre J, Lebreton C, Venat L, Favier L, Louvet C, Abadie-Lacourtoisie S, Lauraine EP, Chardin L, Genestie C, Just PA, Rouleau E, Leary A
Lien Pubmed
Résumé
Platinum-based chemotherapy and surgery are pivotal in managing ovarian cancer (OC), yet prognosis remains poor, and early biomarkers for platinum resistance are needed. The neoadjuvant setting provides an opportunity to evaluate tumor responsiveness to platinum chemotherapy in vivo. This study evaluated whether early measures of platinum response combined with molecular alterations could predict surgical outcomes and survival in patients with OC treated with neoadjuvant chemotherapy (NACT).
Mots clés
Humans, Female, Ovarian Neoplasms, drug therapy, Neoadjuvant Therapy, methods, Middle Aged, Aged, Biomarkers, Tumor, genetics, Adult, Genomic Instability
Référence
JCO Precis Oncol. 2026 01;10:e2500414
